DNTH supply chain intelligence for Dianthus Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Dianthus Therapeutics, Inc. (DNTH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| WUXI-BIOLOGICS | WUXI-BIOLOGICS | 92% | We currently have a sole source relationship with WuXi Biologics for our supply of claseprubart |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activ… |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.… |
| LGNZZ | LGNZZ | 72% | Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing acti… |
| LGNZZ | LGNZZ | 72% | tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to … |
| SNYNF | Sanofi | 72% | . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf… |
| ZBIO | Zenas BioPharma, Inc. | 72% | Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our prod… |
| ZBIO | Zenas BioPharma, Inc. | 72% | . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TENACIA | TENACIA | 92% | Pursuant to the Tenacia Option, if Tenacia exercises the option and pays the Company the option exercise fee related to the second antibody sequence, the Company will grant Tenacia an exclusive licen… |
| ZENAS | ZENAS | 90% | The Company assessed the Zenas Agreements in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), and concluded that it represented a contract with a customer and was within the … |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Act… |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.… |
| LGNZZ | LGNZZ | 72% | tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.… |
| LGNZZ | LGNZZ | 72% | Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing acti… |
| ZBIO | Zenas BioPharma, Inc. | 72% | ature and extent of the potential impacts to our business, results of operations, liquidity and capital resources. For additional information, see the section titled “ Item 1A. Risk Factors ” found e… |
| ZBIO | Zenas BioPharma, Inc. | 72% | Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: ature and extent of the potential i… |
| ALLOY-THERAPEUTICS-LLC | ALLOY-THERAPEUTICS-LLC | 62% | urities and capital expenditures of $0.1 million, partially offset by $127.0 million of proceeds from sales and maturities of investment securities. Cash Flows from Financing Activities For the year … |
| HK-LIMITED | HK-LIMITED | 62% | esources. For additional information, see the section titled “ Risk Factors ” found elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 3… |
| HONG-KONG-CO-LIMITED | HONG-KONG-CO-LIMITED | 62% | esources. For additional information, see the section titled “ Risk Factors ” found elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December 3… |
| IONTAS-LIMITED | IONTAS-LIMITED | 62% | urities and capital expenditures of $0.1 million, partially offset by $127.0 million of proceeds from sales and maturities of investment securities. Cash Flows from Financing Activities For the year … |
| NANJING-LEADS-BIOLABS-CO-LTD | NANJING-LEADS-BIOLABS-CO-LTD | 62% | (i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make payments to IONTAS of up to £ 3.1 million (approximately $ 4.1 million based on the March 3… |
| ZENAS-BIOPHARMA-LIMITED | ZENAS-BIOPHARMA-LIMITED | 62% | ature and extent of the potential impacts to our business, results of operations, liquidity and capital resources. For additional information, see the section titled “ Item 1A. Risk Factors ” found e… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DNTH-DEBT | Debt stack $1.4M | 90% | Market cache reports total debt of $1.4M. |
| DNTH-DEBT-9107 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| DNTH-DEBT-9106 | Warrants outstanding: 0.001 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DNTH-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 243 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| LGNZZ | LIGAND PHARMACEUTICALS INC | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 1 | ['customer', 'supplier'] |
| BHC | Bausch Health Companies Inc. | 100.00 | 2 | |
| XNCR | Xencor, Inc. | 100.00 | 2 | |
| VRDN | Viridian Therapeutics, Inc. | 100.00 | 2 | |
| LLY | Eli Lilly and Company | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 2 | ['supplier'] |
| NUVB | Nuvation Bio Inc. | 100.00 | 2 | |
| ZENAS | ZENAS | 60.75 | 1 | ['receiving'] |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 50.00 | 2 | |
| LONA | LeonaBio, Inc. | 50.00 | 2 | |
| ELUT | Elutia Inc. | 50.00 | 2 | |
| OABIW | OmniAb, Inc. | 50.00 | 2 | |
| SGMO | Sangamo Therapeutics, Inc. | 50.00 | 2 | |
| GSK | GSK plc | 50.00 | 2 |